The DTRC has three main aims: recruitment, diagnosis/assessment and treatment.
Each specific aim has both center-wide and core-specific goals as follows: 1.) Recruitment. To ensure adequate and efficient subject flow for the MHCRC's studies we plan to centralize our existing recruitment efforts. We will recruit a broad range of patients with schizophrenia and related disorders including first-episode patients, chronic patients in acute exacerbation, stable outpatients, chronic inpatients in state facilities, patients with significant co-morbidities, and the homeless. In addition, we will continue to recruit controls from the Normal CONTROLS Unit at the New York State Psychiatric Institute (NYSPI) and to provide the proposed MHCRC with updated diagnoses on this sample. 2.) Diagnosis/Assessment. We will rigorously diagnose and characterize patients participating in the MHCRC's research protocols and broadly sample schizophrenia-related conditions across multiple domains of psychopathology (e.g. trait-related symptoms, course of illness, and neuro-cognitive variables). Core-specific research will build on our previous work studying unawareness deficits and suicidal behavior ion schizophrenia. 3.) Treatment. To provide high quality treatment to patients admitted to either inpatient site-the Schizophrenia Research Unit at Creedmoor (SRU- C) and the Schizophrenia Research Unit at NYSPI (SRU-P)- and the Outpatient Research and Rehabilitation Program (ORR). Core-specific treatment research will focus especially on the use of atypical antipsychotics with refractory patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Center Core Grants (P30)
Project #
5P30MH059342-03
Application #
6495756
Study Section
Clinical Centers and Special Projects Review Committee (CCSP)
Project Start
2001-09-01
Project End
2002-12-31
Budget Start
Budget End
Support Year
3
Fiscal Year
2001
Total Cost
$73,467
Indirect Cost
Name
New York State Psychiatric Institute
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Goetz, Raymond R; Corcoran, Cheryl; Yale, Scott et al. (2007) Validity of a 'proxy'for the deficit syndrome derived from the Positive And Negative Syndrome Scale (PANSS). Schizophr Res 93:169-77
Kimhy, David; Yale, Scott; Goetz, Raymond R et al. (2006) The factorial structure of the schedule for the deficit syndrome in schizophrenia. Schizophr Bull 32:274-8
Kayser, Jurgen; Tenke, Craig E (2006) Principal components analysis of Laplacian waveforms as a generic method for identifying ERP generator patterns: I. Evaluation with auditory oddball tasks. Clin Neurophysiol 117:348-68
Kayser, Jurgen; Tenke, Craig E (2006) Principal components analysis of Laplacian waveforms as a generic method for identifying ERP generator patterns: II. Adequacy of low-density estimates. Clin Neurophysiol 117:369-80
van Berckel, Bart N M; Kegeles, Lawrence S; Waterhouse, Rikki et al. (2006) Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography. Neuropsychopharmacology 31:967-77
Slifstein, Mark; Narendran, Raj; Hwang, Dah-Ren et al. (2004) Effect of amphetamine on [(18)F]fallypride in vivo binding to D(2) receptors in striatal and extrastriatal regions of the primate brain: Single bolus and bolus plus constant infusion studies. Synapse 54:46-63
Slifstein, Mark; Hwang, Dah-Ren; Huang, Yiyun et al. (2004) In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates. Psychopharmacology (Berl) 175:274-86
Waterhouse, Rikki N; Slifstein, Mark; Dumont, Filip et al. (2004) In vivo evaluation of [11C]N-(2-chloro-5-thiomethylphenyl)-N'-(3-methoxy-phenyl)-N'-methylguanidine ([11C]GMOM) as a potential PET radiotracer for the PCP/NMDA receptor. Nucl Med Biol 31:939-48
Huang, Yiyun; Hwang, Dah-Ren; Bae, Sung-A et al. (2004) A new positron emission tomography imaging agent for the serotonin transporter: synthesis, pharmacological characterization, and kinetic analysis of [11C]2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylphenylamine ([11C]AFM). Nucl Med Biol 31:543-56
Harkavy-Friedman, Jill M; Nelson, Elizabeth A; Venarde, David F et al. (2004) Suicidal behavior in schizophrenia and schizoaffective disorder: examining the role of depression. Suicide Life Threat Behav 34:66-76

Showing the most recent 10 out of 30 publications